Evidence map›Paper›PMID 31723084›Full record

ArticleAnnals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia2020

MiR-26b Suppresses the Development of Stanford Type A Aortic Dissection by Regulating HMGA2 and TGF-β/Smad3 Signaling Pathway.

Ping Yang, Peng Wu, Xing Liu, Jian Feng, Shuzhan Zheng, Yan Wang, Zhongcai Fan

Abstract read
In one paragraph

Article in Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Non-coding RNAs Regulate the Pathogenesis of Aortic Dissection.Frontiers in cardiovascular medicine · 2022
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ping YangDepartment of Vasculocardiology, the Affiliated Hospital of Southwest Medical University, Luzhou, China.
Peng WuDepartment of Vasculocardiology, Ya'an People's Hospital, Ya'an, China.
Xing LiuDepartment of Vasculocardiology, the Affiliated Hospital of Southwest Medical University, Luzhou, China.
Jian FengDepartment of Vasculocardiology, the Affiliated Hospital of Southwest Medical University, Luzhou, China.
Shuzhan ZhengDepartment of Vasculocardiology, the Affiliated Hospital of Southwest Medical University, Luzhou, China.
Yan WangDepartment of Vasculocardiology, the Affiliated Hospital of Southwest Medical University, Luzhou, China.
Zhongcai FanDepartment of Vasculocardiology, the Affiliated Hospital of Southwest Medical University, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStanford type A aortic dissection (TAAD) is one of the most dangerous cardiovascular diseases. MicroRNAs (miRNAs) have been considered as potential therapeutic targets for TAAD. In this present study, we aimed to investigate the functional role and regulatory mechanism of miR-26b in TAAD development. MATERIALS AND

methodsMiR-26b mRNA expression was detected by real-time polymerase chain reaction (RT-PCR) and protein levels were measured by Western blot. Verifying the direct target of miR-26b was used by dual luciferase assay, RT-PCR, and Western blot. Cell Counting Kit-8 (CCK-8) and TUNEL staining assays were applied for detecting rat aortic vascular smooth muscle cells (VSMCs) viability and apoptosis, respectively.

resultsWe found that miR-26b was under-expressed in TAAD patients and closely associated with the poor prognosis of TAAD patients. Re-expression of miR-26b facilitated while knockdown of miR-26b inhibited VSMC proliferation. However, miR-26b showed the opposite effect on cell apoptosis. More importantly, high-mobility group AT-hook 2 (HMGA2) was verified as the direct target of miR-26b. Furthermore, transforming growth factor beta (TGF-β)/Smad3 signaling pathway was involved in the development of TAAD modulated by miR-26b.

conclusionmiR-26b impeded TAAD development by regulating HMGA2 and TGF-β/Smad3 signaling pathway, which provided a potential biomarker for TAAD treatment.

Indexed as

AdultAnimalsAorta, ThoracicAortic Aneurysm, ThoracicAortic DissectionApoptosisCells, CulturedFemaleGene Expression RegulationHMGA2 ProteinHumansMaleMicroRNAsMiddle AgedMuscle, Smooth, VascularMyocytes, Smooth MuscleHMGA2 ProteinHMGA2 protein, humanHMGA2 protein, ratMicroRNAsMIRN26 microRNA, humanMIRN26 microRNA, ratSmad3 ProteinSmad3 protein, ratTransforming Growth Factor beta39 pathwayHMGA2miR-26bStanford type A aortic dissectionTGF-β/Smad3

Identifiers

PMID31723084
PMCPMC7303312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.